Profile data is unavailable for this security.
About the company
Windlas Biotech Limited is an India-base domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The Company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP). It develops and manufactures products to customers and consumers across India and some emerging markets, internationally. The Company specializes in manufacturing oral solids dosage and oral liquids dosage (OSD/OLD). It also extends to delivering specialty capabilities such as high potency, restricted chemicals, and low solubility products. Its product categories include pain management, gastro management, nutritional/food supplement, derma and hair care, respiratory management, diabetic management, cardiac management, neuro psychiatric management, tyro care, women healthcare and others.
- Revenue in INR (TTM)6.31bn
- Net income in INR581.87m
- Incorporated2001
- Employees1.05k
- LocationWindlas Biotech Ltd40/1 Mohabewala Industrial AreaDEHARADUN 248110IndiaIND
- Websitehttps://windlas.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bliss GVS Pharma Ltd | 7.70bn | 754.54m | 11.09bn | 763.00 | 14.95 | 1.15 | 10.27 | 1.44 | 7.08 | 7.08 | 72.86 | 92.39 | 0.6498 | 3.45 | 1.95 | -- | 6.88 | 6.46 | 8.37 | 8.22 | 50.39 | 44.21 | 10.59 | 9.92 | 4.34 | 17.97 | 0.0905 | 7.93 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Vimta Labs Ltd | 3.18bn | 410.09m | 11.14bn | 1.37k | 27.55 | 3.48 | 14.81 | 3.50 | 18.24 | 18.24 | 141.64 | 144.20 | 0.8349 | 3.23 | 3.81 | -- | 10.76 | 10.53 | 12.60 | 12.77 | 76.02 | 73.65 | 12.89 | 12.16 | 2.46 | 24.79 | 0.0566 | 11.15 | 0.0223 | 8.40 | -14.87 | 10.13 | 35.88 | 0.00 |
| Beta Drugs Ltd | 2.56bn | 347.57m | 11.76bn | 315.00 | 33.83 | 8.28 | 25.69 | 4.59 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
| Syncom Formulations (India) Ltd | 2.63bn | 253.14m | 11.82bn | 799.00 | 36.97 | 4.10 | 39.34 | 4.49 | 0.34 | 0.34 | 3.56 | 3.07 | 0.6732 | 7.42 | 2.95 | -- | 6.47 | 7.50 | 9.00 | 10.23 | 40.44 | 34.59 | 9.61 | 9.38 | 2.38 | 5.57 | 0.201 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 12.26bn | 38.00 | 130.17 | 47.18 | 136.47 | 27.22 | 15.98 | 15.98 | 90.25 | 44.09 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
| Lincoln Pharmaceuticals Ltd | 5.81bn | 933.05m | 12.33bn | 1.70k | 13.22 | 2.08 | 11.87 | 2.12 | 46.58 | 46.58 | 289.81 | 295.98 | 0.9017 | 3.78 | 3.90 | -- | 14.49 | 13.95 | 16.61 | 16.54 | 52.06 | 51.21 | 16.07 | 14.71 | 4.01 | 60.95 | 0.0018 | -- | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Kopran Ltd | 6.15bn | 509.56m | 12.49bn | 394.00 | 24.68 | 2.54 | 19.57 | 2.03 | 10.50 | 10.50 | 126.95 | 101.90 | 0.8824 | 2.99 | 3.28 | -- | 7.32 | 8.47 | 10.22 | 12.23 | 34.60 | 34.18 | 8.29 | 8.89 | 1.44 | 43.23 | 0.168 | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Ngl Fine Chem Ltd | 3.39bn | 413.43m | 14.80bn | 343.00 | 35.79 | 5.63 | 27.94 | 4.37 | 66.92 | 66.92 | 548.61 | 425.11 | 1.05 | 4.51 | 4.36 | -- | 12.87 | 15.06 | 16.61 | 19.58 | 53.18 | 46.79 | 12.20 | 13.15 | 1.96 | 30.64 | 0.1218 | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Windlas Biotech Ltd | 6.31bn | 581.87m | 15.14bn | 1.05k | 25.93 | 3.35 | 21.13 | 2.40 | 27.94 | 27.94 | 302.99 | 216.33 | 1.09 | 5.79 | 4.99 | -- | 10.07 | -- | 13.50 | -- | 37.21 | -- | 9.22 | -- | 2.15 | 58.58 | 0.008 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| Hester Biosciences Ltd | 3.05bn | 188.89m | 16.09bn | 693.00 | 75.97 | 5.51 | 41.95 | 5.28 | 24.89 | 24.89 | 392.38 | 343.01 | 0.4572 | 1.20 | 3.85 | -- | 3.18 | 6.15 | 4.00 | 7.69 | 68.52 | 68.83 | 6.95 | 12.83 | 1.31 | 1.84 | 0.4466 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| Zota Health Care Ltd | 1.80bn | -143.48m | 16.43bn | 338.00 | -- | 17.79 | 286.03 | 9.10 | -5.59 | -5.59 | 70.40 | 34.81 | 0.9341 | 2.02 | 6.55 | -- | -7.42 | -1.38 | -10.54 | -1.85 | 46.43 | 36.48 | -7.95 | -1.33 | 0.7851 | -2.62 | 0.5143 | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| SMS Pharmaceuticals Ltd | 7.09bn | 498.26m | 17.61bn | 1.10k | 35.32 | 3.28 | 21.82 | 2.48 | 5.89 | 5.89 | 83.84 | 63.36 | 0.7413 | 2.18 | 3.69 | -- | 5.14 | 5.43 | 7.41 | 7.33 | 29.83 | 32.67 | 6.94 | 7.87 | 0.905 | 3.63 | 0.3436 | 6.59 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Themis Medicare Ltd | 3.82bn | 435.24m | 20.24bn | 996.00 | 46.58 | 5.36 | 36.29 | 5.30 | 4.72 | 4.72 | 41.41 | 41.03 | 0.7067 | 1.96 | 2.36 | -- | 8.06 | 11.12 | 11.07 | 16.46 | 64.19 | 61.49 | 11.40 | 14.96 | 1.44 | -- | 0.2023 | 8.28 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2023 | 1.95m | 9.40% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 May 2024 | 201.84k | 0.97% |
| Macquarie Funds Management Hong Kong Ltd.as of 30 Nov 2021 | 20.45k | 0.10% |
| American Century Investment Management, Inc.as of 09 May 2024 | 461.00 | 0.00% |
